Increased tryptophan degradation in patients with bronchus carcinoma

European Journal of Cancer Care

Volumn 19, Issue 6, 2010, Pages 803-808

  Engin, A B ^a   Ozkan, Y ^a   Fuchs, D ^b   Yardim Akaydin, S ^a  

^a GAZI UNIVERSITY   (Turkey)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Indoleamine (2,3) dioxygenase; Lung cancer; Neopterin; Tryptophan

Indexed keywords

C REACTIVE PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; NEOPTERIN; TRYPTOPHAN; TUMOR PROTEIN;

ARTICLE; BLOOD; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; METABOLISM; MIDDLE AGED; PILOT STUDY;

BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPTERIN; PILOT PROJECTS; SMALL CELL LUNG CARCINOMA; TRYPTOPHAN;

EID: 79955646295     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2009.01122.x     Document Type: Article

References (34)

1. Arenberg D.A., Keane M.P., DiGiovine B., Kunkel S.L., Strom S.R. & Burdick M.D. (2000) Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer Immunology and Immunotherapy 49, 63-70.
2. Arpin D., Trillet-Lenoir V., Lasset C., Souquet P.J., Riou R. & Yoanidis I. (1993) Value of C-reactive protein determination in small cell lung cancer. Bulletin du Cancer 80, 1063-1068.
3. Astigiano S., Morandi B., Costa R., Mastracci L., D'Agostino A. & Ratto G.B. (2005) Eosinophil granulocytes account for indoleamine 2, 3-dioxygenase-mediated immune escape in human non-small cell lung cancer. Neoplasia 7, 390-396.
4. Brandacher G., Perathoner A., Ladurner R., Schneeberger S., Obrist P. & Winkler C. (2006a) Prognostic value of indoleamine (2, 3)-dioxygenase expression in colorectal cancer: impact on tumor-infiltrating T-cells. Clinical Cancer Research 212, 1144-1151.
5. Brandacher G., Schroecksnadel K., Winkler C., Margreiter R. & Fuchs D. (2006b) Antitumoral activity of interferon-γ involved in impaired immune function in cancer patients. Current Drug Metabolism 7, 599-612.
6. Burke F., Knowles R.G., East N. & Balkwill F.R. (1995) The role of indoleamine (2, 3)-dioxygenase in the anti-tumour activity of human interferon-gamma in vivo. International Journal of Cancer 60, 115-122.
7. Caputi M., Russo G., Esposito V., Mancini A. & Giordano A. (2005) Role of cell-cycle regulators in lung cancer. Journal of Cellular Physiology 205, 319-327.
8. Denz H., Orth B., Weiss G., Herrmann R., Huber P., Wachter H. & Fuchs D. (1993) Weight loss in patients with hematological neoplasias is associated with immune system stimulation. Clinical Investigation 71, 37-41.
9. Domont J., Soria J.C. & Le Chevalier T. (2005) Adjuvant chemotherapy in early-stage non-small cell lung cancer. Seminars in Oncology 32, 279-283.
10. Dowlati A., Levitan N. & Remick S.C. (1999) Evaluation of interleukin-6 in bronchoalveolar lavage fluid and serum of patients with lung cancer. Journal of Laboratory and Clinical Medicine 134, 405-409.
11. Friberg M., Jennings R., Alsarraj M., Dessureault S., Cantor A. & Extermann M. (2002) Indoleamine (2, 3)-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. International Journal of Cancer 101, 151-155.
12. Hiraoka K., Miyamoto M., Cho Y., Suzuoki M., Oshikiri T. & Nakakubo Y. (2006) Concurrent infiltration by CD8(+) T cells and CD4(+) T cells is a favourable prognostic factor in non-small-cell lung carcinoma. British Journal of Cancer 94, 275-280.
13. Hou D.Y., Muller A.J., Sharma M.D., DuHadaway J., Banerjee T., Johnson M., Mellor A.L., Prendergast G.C. & Munn D.H. (2007) Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Research 67, 792-801.
14. Huang A., Fuchs D., Widner B., Glover C., Henderson D.C. & Allen-Mersh T.G. (2002) Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. British Journal of Cancer 86, 1691-1696.
15. Junker K. (2006) Current morphological diagnosis of malignant lung tumors. Pathologe 27, 90-98.
16. Loeb S., Königsrainer A., Zieker D., Brücher B.L., Rammensee H.G., Opelz G. & Terness P. (2009) IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunology and Immunotherapy 58, 153-157.
17. Mohamed K.H., Mobasher A.A., Yousef A.R., Salah A., El-Naggar I.Z. & Ghoneim A.H. (2001) BAL neopterin: a novel marker for cell-mediated immunity in patients with pulmonary tuberculosis and lung cancer. Chest 119, 776-780.
18. Murr C., Widner B., Wirleitner B. & Fuchs D. (2002) Neopterin as a marker for immune system activation. Current Drug Metabolism 3, 175-187.
19. Ortegel J.W., Staren E.D., Faber L.P., Warren W.H. & Braun D.P. (2000) Cytokine biosynthesis by tumor-infiltrating T lymphocytes from human non-small-cell lung carcinoma. Cancer Immunology and Immunotherapy 48, 627-634.
20. Ozaki Y., Edelstein M.P. & Duch D.S. (1988) Induction of indoleamine (2, 3)-dioxygenase: a mechanism of the antitumor activity of interferon gamma. Proceedings of the National Academy of Sciences of the United States of America 85, 1242-1246.
21. Prommegger R., Widner B., Murr C., Unger A., Fuchs D. & Salzer G.M. (2000) Neopterin: a prognostic variable in operations for lung cancer. Annals of Thoracic Surgery 70, 1861-1864.
22. Reibnegger G., Fuchs D., Fuith L.C., Hausen A., Werner E.R. & Werner-Felmayer G. (1991) Neopterin as a marker for activated cell-mediated immunity: application in malignant disease. Cancer Detection and Prevention 15, 483-490.
23. Rossi A., Maione P., Colantuoni G., Guerriero C., Ferrara C., Del Gaizo F. & Nicolella D. (2005) Treatment of small cell lung cancer in the elderly. Oncologist 10, 399-411.
24. Schroecksnadel K., Winkler C., Fuith L.C. & Fuchs D. (2005) Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Letters 223, 323-329.
25. Spiro S.G. & Silvestri G.A. (2005) One hundred years of lung cancer. American Journal of Respiratory and Critical Care Medicine 172, 523-529.
26. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D. & Parmentier N. (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine (2, 3)-dioxygenase. Nature Medicine 9, 1269-1274.
27. Weinlich G., Murr C., Richardsen L., Winkler C. & Fuchs D. (2007) Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology 214, 8-14.
28. Werner E.R., Bitterlich G., Fuchs D., Hausen A., Reibnegger G., Szabo G., Dierich M.P. & Wachter H. (1987) Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sciences 41, 273-280.
29. Werner-Felmayer G., Werner E.R., Fuchs D., Hausen A., Reibnegger G. & Wachter H. (1989) Characteristics of interferon induced tryptophan metabolism in human cells in vitro. Biochimica et Biophysica Acta 1012, 140-147.
30. Widner B., Werner E.R., Schennach H., Wachter H. & Fuchs D. (1997) Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clinical Chemistry 43, 2424-2426.
31. Wirleitner B., Reider D., Ebner S., Böck G., Widner B., Jaeger M., Schennach H., Romani N. & Fuchs D. (2002) Monocyte-derived dendritic cells release neopterin. Journal of Leukocyte Biology 72, 1148-1153.
32. Wood K.J. & Sawitzki B. (2005) Interferon gamma: a crucial role in the function of induced regulatory T cells in vivo. Trends in Immunology 27, 183-187.
33. Yasui H., Takai K., Yoshida R. & Hayaishi O. (1986) Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine (2, 3)-dioxygenase: its possible occurrence in cancer patients. Proceedings of the National Academy of Sciences of the United States of America 83, 6622-6626.
34. Yoshida R., Park S.W., Yasui H. & Takikawa O.J. (1988) Tryptophan degradation in transplanted tumor cells undergoing rejection. Immunology 141, 2819-2823.